Salim Syed
Stock Analyst at Mizuho
(3.10)
# 2,444
Out of 5,182 analysts
85
Total ratings
47.14%
Success rate
1.3%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Salim Syed
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| AUTL Autolus Therapeutics | Maintains: Outperform | $12 → $10 | $1.55 | +545.16% | 1 | Mar 31, 2026 | |
| SNDX Syndax Pharmaceuticals | Maintains: Outperform | $45 → $43 | $23.33 | +84.31% | 1 | Mar 31, 2026 | |
| NKTX Nkarta | Maintains: Outperform | $14 → $12 | $3.32 | +261.45% | 9 | Mar 31, 2026 | |
| ELVN Enliven Therapeutics | Maintains: Outperform | $41 → $45 | $45.89 | -1.94% | 2 | Mar 25, 2026 | |
| WVE Wave Life Sciences | Maintains: Outperform | $22 → $27 | $7.34 | +267.85% | 6 | Mar 25, 2026 | |
| CYTK Cytokinetics | Maintains: Outperform | $84 → $100 | $65.80 | +51.98% | 8 | Mar 18, 2026 | |
| BBIO BridgeBio Pharma | Maintains: Outperform | $91 → $106 | $76.18 | +39.14% | 8 | Mar 18, 2026 | |
| MAZE Maze Therapeutics | Initiates: Outperform | $97 | $25.69 | +277.58% | 1 | Mar 10, 2026 | |
| INCY Incyte | Upgrades: Outperform | $90 → $121 | $96.22 | +25.75% | 1 | Dec 8, 2025 | |
| ASMB Assembly Biosciences | Maintains: Outperform | $29 → $40 | $27.01 | +48.09% | 2 | Nov 20, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $207 → $169 | $185.95 | -9.12% | 16 | May 7, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $235 → $280 | $344.86 | -18.81% | 8 | May 7, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $100 → $117 | $133.29 | -12.22% | 7 | May 5, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $113 → $163 | $60.55 | +169.20% | 3 | Sep 10, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Outperform | $25 → $18 | $4.99 | +260.72% | 4 | Aug 16, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $82 → $99 | $55.54 | +78.25% | 3 | Mar 6, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $28 → $21 | $1.82 | +1,053.85% | 5 | Nov 16, 2022 |
Autolus Therapeutics
Mar 31, 2026
Maintains: Outperform
Price Target: $12 → $10
Current: $1.55
Upside: +545.16%
Syndax Pharmaceuticals
Mar 31, 2026
Maintains: Outperform
Price Target: $45 → $43
Current: $23.33
Upside: +84.31%
Nkarta
Mar 31, 2026
Maintains: Outperform
Price Target: $14 → $12
Current: $3.32
Upside: +261.45%
Enliven Therapeutics
Mar 25, 2026
Maintains: Outperform
Price Target: $41 → $45
Current: $45.89
Upside: -1.94%
Wave Life Sciences
Mar 25, 2026
Maintains: Outperform
Price Target: $22 → $27
Current: $7.34
Upside: +267.85%
Cytokinetics
Mar 18, 2026
Maintains: Outperform
Price Target: $84 → $100
Current: $65.80
Upside: +51.98%
BridgeBio Pharma
Mar 18, 2026
Maintains: Outperform
Price Target: $91 → $106
Current: $76.18
Upside: +39.14%
Maze Therapeutics
Mar 10, 2026
Initiates: Outperform
Price Target: $97
Current: $25.69
Upside: +277.58%
Incyte
Dec 8, 2025
Upgrades: Outperform
Price Target: $90 → $121
Current: $96.22
Upside: +25.75%
Assembly Biosciences
Nov 20, 2025
Maintains: Outperform
Price Target: $29 → $40
Current: $27.01
Upside: +48.09%
May 7, 2025
Maintains: Outperform
Price Target: $207 → $169
Current: $185.95
Upside: -9.12%
May 7, 2025
Maintains: Neutral
Price Target: $235 → $280
Current: $344.86
Upside: -18.81%
May 5, 2025
Maintains: Outperform
Price Target: $100 → $117
Current: $133.29
Upside: -12.22%
Sep 10, 2024
Maintains: Outperform
Price Target: $113 → $163
Current: $60.55
Upside: +169.20%
Aug 16, 2024
Upgrades: Outperform
Price Target: $25 → $18
Current: $4.99
Upside: +260.72%
Mar 6, 2024
Maintains: Buy
Price Target: $82 → $99
Current: $55.54
Upside: +78.25%
Nov 16, 2022
Maintains: Buy
Price Target: $28 → $21
Current: $1.82
Upside: +1,053.85%